(1 - 9 von 9
)
Angle PLC: Parsortix enables CTC molecular characterisation
www.finanznachrichten.de
Professor Robert Zeillinger, Head of the Molecular Oncology Group at the Medical University of Vienna, commented: "In the study we have demonstrated that ANGLE's Parsortix™ system addresses key ...
Ovarian Cancer Collaboration with the Medical University of Vienna |...
www.technologynetworks.com
Collaboration agreement to investigate the clinical use of the Parsortix system for ovarian cancer.
Researchers successfully use Parsortix system in ovarian cancer drug...
medicalxpress.com
Robert Zeillinger, Head of the Molecular Oncology Group at the Medical University of Vienna. 'This opens up completely new approaches to ...
sortiert nach Relevanz / Datum